SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03849768

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

A Randomized, Open-Label, Multi Center, Phase III Study to Assess the Efficacy and Safety of HS-10296 Versus Gefitinib as First-Line Treatment in Patients With EGFR Mutation Positive, Locally Advanced or Metastatic NSCLC

This is a randomized, open-Label, multicenter, Phase III study.

NCT03849768 Non Small Cell Lung Cancer
MeSH: Carcinoma, Non-Small-Cell Lung
HPO: Non-small cell lung carcinoma

2 Interventions

Name: HS-10296

Description: Drug: HS-10296 110 mg/55 mg + placebo The initial dose of HS-10296 110 mg once daily can be reduced to 55 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Type: Drug

HS-10296

Name: Gefitinib

Description: Drug: Gefitinib 250 mg + placebo The initial dose of Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Type: Drug

Gefitinib


Primary Outcomes

Description: To assess the efficacy of HS-10296 compared with gefitinib as first line therapy to EGFRm+, locally advanced or metastatic NSCLC patients by assessment of progression free survival (PFS) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

Measure: Assess the efficacy of HS-10296: progression free survival (PFS)

Time: From baseline, then every 6 weeks, until disease progression or discontinuation from study. From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.

Secondary Outcomes

Description: Overall survival (OS)

Measure: Assess the anti-tumor activity: OS

Time: Start of study drug to Survival Endpoint through study completion, an average of 3 years.

Description: Objective response rate (ORR)

Measure: Assess the anti-tumor activity: ORR

Time: From baseline, then every 6 weeks, until disease progression or discontinuation from study. ORR is defined as the percentage of patients who have at least 1 response of CR or PR prior to any evidence of progression assessed up to 24 months.

Description: Duration of response (DoR)

Measure: Assess the anti-tumor activity: DoR

Time: DoR is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression assessed up to 24 months.

Description: Disease control rate (DCR)

Measure: Assess the anti-tumor activity: DCR

Time: From baseline, then every 6 weeks, until disease progression or discontinuation from study. The DCR is defined as the proportion of patients with a best overall response of CR, PR, or SD assessed up to 24 months.

Description: Depth of response (DepOR)

Measure: Assess the anti-tumor activity: DepOR

Time: From baseline, then every 6 weeks, until disease progression or discontinuation from study. DepOR is defined as the sum of the lengths of the longest diameters of the RECIST 1.1 target lesions up to 24 months.

Description: Number of adverse events (AEs)/serious adverse events (SAEs)

Measure: Assess the safety of HS-10296: Number of AEs/SAEs

Time: Continuously throughout the study until 28 days after HS-10296 discontinuation

Description: Incidence and severity of AEs/SAEs assessed by CTCAE v4.03

Measure: Assess the safety of HS-10296: Incidence and severity of AEs/SAEs

Time: Continuously throughout the study until 28 days after HS-10296 discontinuation

Description: Dose interruptions

Measure: Assess the safety of HS-10296: Number of Participants with Dose interruptions

Time: Continuously throughout the study until 28 days after HS-10296 discontinuation.

Description: Dose reductions

Measure: Assess the safety of HS-10296: Number of Participants with Dose reductions

Time: Continuously throughout the study until 28 days after HS-10296 discontinuation.

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 L858R

4. The tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either or in combination with other EGFR mutations assessed by central testing using tumour tissue sample or blood sample. --- L858R ---



HPO Nodes


HPO:
Non-small cell lung carcinoma
Genes 2
TP53 BAP1